S. Topalian

Publications261
h-index93
Citations79,235
Highly Influential Citations2,245
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Rosenberg
  • 1,499 Publications • 208,087 Citations
  • J. Taube
  • 262 Publications • 43,400 Citations
  • D. Pardoll
  • 654 Publications • 117,012 Citations
  • J. Wolchok
  • 886 Publications • 130,608 Citations
  • Publications
  • Influence
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
TLDR
Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer; the adverse-event profile does not appear to preclude its use.
View on PubMed
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
TLDR
Antibody-mediated blockade of PD-L1 induced durable tumor regression and prolonged stabilization of disease in patients with advanced cancers, including non-small-cell lung cancer, melanoma, and renal-cell cancer.
View on PubMed
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
TLDR
Induction of the B7-H1/PD-1 pathway may represent an adaptive immune resistance mechanism exerted by tumor cells in response to endogenous antitumor activity and may explain how melanomas escape immune destruction despite endogenous antitUMor immune responses.
View on Publisher
Immune checkpoint blockade: a common denominator approach to cancer therapy.
View on PubMed
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
TLDR
The ability to specifically confer tumor recognition by autologous lymphocytes from peripheral blood by using a retrovirus that encodes a T cell receptor is reported.
View on Publisher
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
TLDR
The adoptive transfer of highly selected tumor-reactive T cells directed against overexpressed self-derived differentiation antigens after a nonmyeloablative conditioning regimen resulted in the persistent clonal repopulation of T cells in cancer patients, leading to regression of the patients' metastatic melanoma as well as to the onset of autoimmune melanocyte destruction.
View on Publisher
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.
TLDR
Blocking the PD-1 immune checkpoint with intermittent antibody dosing is well tolerated and associated with evidence of antitumor activity, and tumor cell surface B7-H1 expression appeared to correlate with the likelihood of response to treatment.
View on PubMed
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
TLDR
Bvacizumab can significantly prolong the time to progression of disease in patients with metastatic renal-cell cancer, and this trial was stopped after the interim analysis met the criteria for early stopping.
View on PubMed
Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy
TLDR
Tumor PD-L1 expression reflects an immune-active microenvironment and, while associated other immunosuppressive molecules, including PD-1 andPD-L2, is the single factor most closely correlated with response to anti–PD-1 blockade.
View on Publisher
Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer
TLDR
Nivolumab was associated with few side effects, did not delay surgery, and induced a major pathological response in 45% of resected tumors, and the tumor mutational burden was predictive of the pathological response to PD‐1 blockade.
View on Wolters Kluwer
...
...